Nasus Pharma Ltd. · AMEX:NSRX
Nasus Pharma — IPO Roadshow (July 2025)
29 slides from Nasus Pharma's IPO roadshow presentation, Jul 30, 2025
Slide 1: A New Frontier for Intranasal Drug Delivery
File Pursuant to Rule 433 Issuer Free Writing Prospectus Dated: July 30, 2025 Relating to Preliminary Prospectus Dated: July 28, 2025 Registration No.: 333-288582 A NEW FRONTIER FOR INTRANASAL DRUG DELIVERY Investor Presentation – July 2025 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation of Nasus Pharma Ltd. contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities law. Words such as “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions
Slide 3: Free Writing Prospectus
Free Writing Prospectus This presentation highlights information about Nasus Pharma Ltd. (“Nasus,” “we,” “us,” or the “Company”) and the proposed public offering to which this presentation relates. Because this presentation is a summary, it does not contain all of the information that you should con
Slide 4: Offering Summary
Offering Summary Issuer Nasus Pharma Ltd. Proposed Listing NYSE American: NSRX Expected Offering Size: $10,000,000 Shares Offered: Ordinary Shares (with 15% Over-allotment Option) Expected Price Range: $8.00 - $10.00 per Ordinary Share Use of Proceeds: • Approximately $6 million to $7 million for th
Slide 5: Nasus is Uniquely Positioned to Address Medical Emergencies via Intranasal Drug Delivery
Nasus is Uniquely Positioned to Address Medical Emergencies via Intranasal Drug Delivery Proprietary Nasax® Initial focus on life NS002 intranasal Successful Phase 3 of technology aims to enhance threatening emergencies Epinephrine in Phase 2* intranasal Naloxone (NS001) intranasal drug absorption d
Slide 6: Robust Asset Pipeline Setting Up Potential for Long Term Growth
Robust Asset Pipeline Setting Up Potential for Long Term Growth Addressing Significant Emergency Indications Drug Candidate Molecule Indication Preclinical Phase 1 Phase 2 Pivotal Trial Next Milestone Two additional Phase 2 studies NS – 002 Epinephrine Anaphylaxis Phase 2 completed March 2023 planne
Slide 7: Proprietary Nasax Platform Enables Superior Drug Absorption
Proprietary Nasax® Platform Enables Superior Drug Absorption Greater intranasal absorption area enables faster delivery and higher maximal drug concentration compared to liquid formulations Liquid formulation Powder formulation Nasax® – proprietary powder formulation for intranasal delivery comprise
Slide 8: Phase 3 Study Demonstrates Nasax Platform Delivers Naloxone Faster Compared to Narcan
Phase 3 Study Demonstrates Nasax® Platform Delivers Naloxone Faster Compared to Narcan In our phase 3 (n=42) intranasal naloxone study (NS-001), our formulation provided faster delivery and higher mean absorption of naloxone compared to Narcan The results of our phase 3 study further validated our N
Slide 9: NS002: Intranasal Epinephrine
NS002: INTRANASAL EPINEPHRINE
Slide 10: Anaphylaxis: A Time-Critical Medical Emergency
Anaphylaxis: A Time-Critical Medical Emergency Anaphylaxis is a severe allergic reaction; fatal in ~1% of cases1 The standard of care for anaphylaxis is Epinephrine – this is typically self-administered via an Epinephrine auto-injector (EAI) or given via intramuscular (IM) injection by a healthcare
Slide 11: NS002 Designed to Address the Limitations of Intramuscular Epinephrine
NS002 Designed to Address the Limitations of Intramuscular Epinephrine The proposed solution: Expensive autoinjectors1 with a NS002 12-18 month shelf-life Epinephrine autoinjectors are expensive (>$600 before Product candidate the introduction of generics) aims to offer a needle- Prices remained hig
Slide 12: Anaphylaxis: A Growing Opportunity in a Large Market
Anaphylaxis: A Growing Opportunity in a Large Market ~1-3% Estimated prevalence of anaphylaxis among the ~$2.3B Global Epinephrine market in 20242 global population1 +6.5% ~40M Patients with type 1 allergies in the U.S.3 CAGR From 2010 to 20233 ~20M Patients experience severe type I allergic reactio
Slide 13: NS002: Pilot Study Overview
NS002: Pilot Study Overview 12 healthy adults with allergic rhinitis (9 male, 3 female) Screening: positive to skin allergen test Period 1 Period 2 Day 1 Day 2 Day 3 2-3 weeks washout Day 1 Day 2 Single IM injection Nasus Product in Nasal allergen Nasus Product 1.6mg Nasal allergen of EpiPen one nos
Slide 14: Pilot Study Results Show NS002 Epinephrine Absorbed into Bloodstream Faster than EpiPen
Pilot Study Results Show NS002 Epinephrine Absorbed into Bloodstream Faster than EpiPen Pilot Study Pharmacokinetics (PK) Plasma epinephrine – geometric mean – 60 min. 14
Slide 15: NS002 Pilot Study Demonstrated Faster and Higher Maximal Epinephrine Absorption Compared to EpiPen
NS002 Pilot Study Demonstrated Faster and Higher Maximal Epinephrine Absorption Compared to EpiPen Pilot study PK – baseline corrected time medians Area Under Curve Tmax median (min.) 20.00 16.50 15.00 Tmax (min.) 9.00 8.98 10.00 5.99 5.00 2.50 0.00 EpiPen Nasus 1.6mg Nasus Nasus 3.2mg Nasus 1.6mg+A
Slide 16: NS002 PD Results Demonstrated Comparable Epinephrine Activity to EpiPen
NS002 PD Results Demonstrated Comparable Epinephrine Activity to EpiPen Pilot study pharmacodynamics (PD) Systolic Blood Pressure 125 120 SBP (mm Hg) EpiPen 115 Nasus 1.6mg normal condition 110 Nasus 1.6mg allergenic challenge 105 Nasus 3.2mg normal condition Nasus 3.2mg allergenic challenge 100 0 0
Slide 17: NS002: Phase 2 Study Designed to Assess Safety and Tolerability, Test Bioavailability, and Optimize Dose
NS002: Phase 2 Study Designed to Assess Safety and Tolerability, Test Bioavailability, and Optimize Dose for Phase 3 Arm 1: N=6 1w B 1w C A Nasus spray 3.6mg Nasus spray 4.0mg EpiPen in one nostril in one nostril Screening 12 healthy volunteers, age 18-55 B 1w A 1w C Nasus spray 3.6mg Nasus spray 4.
Slide 18: Phase 2 Study: More Patients Achieved Hemodynamic Therapeutic Threshold by NS002 Compared to EpiPen
Phase 2 Study: More Patients Achieved Hemodynamic Therapeutic Threshold of Epinephrine by NS002 Compared to EpiPen at 6 Minutes Phase 2 PK results Plasma Epinephrine Results 12 healthy subjects Proportion of subjects achieving clinical threshold of 100pg/mL at 6min 6min EpiPen 55 % Nasus 3.6mg 72 %
Slide 19: Phase 2 Study: NS002 Achieves Faster Epinephrine Plasma Concentration than EpiPen
Phase 2 Study: NS002 Achieves Faster Epinephrine Plasma Concentration than EpiPen Phase 2 PK results Mean AUC0-4min +SD Mean AUC0-10min +SD 70 140 60 120 Mean AUC h*pg/mL Mean AUC h*pg/mL 50 100 40 80 63.96 30 27.44 60 50.99 20 14.17 40 27.38 10 5.85 20 0 0 EpiPen Nasus 3.6mg Nasus 4.0mg EpiPen Nasu
Slide 20: Phase 2 Study: NS002 Achieves Faster Absorption and Greater Concentration of Epinephrine Compared to EpiPen
Phase 2 Study: NS002 Achieves Faster Absorption and Greater Concentration of Epinephrine Compared to EpiPen – Including Time to Hemodynamic Therapeutic Threshold 100pg/ml Phase 2 Results - Cmax, Tmax and T100pg/mL Tmax (median, minutes) T100pg/mL (median, minutes) Cmax (Geometric mean + SD) 1400 16
Slide 21: Phase 2 Study: NS002 Demonstrated Comparable Epinephrine Activity to EpiPen
Phase 2 Study: NS002 Demonstrated Comparable Epinephrine Activity to EpiPen Phase 2 PD results Heart Rate Systolic Blood Pressure 140 90 130 85 Systolic BP (mean) 120 80 HR (mean) 110 75 100 70 90 65 0 20 40 60 80 100 120 0 20 40 60 80 100 120 Time (min.) Time (min.) Diastolic Blood Pressure Respira
Slide 22: NS002: Phase 2 Results Summary
NS002: Phase 2 Results Summary NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors NS002 REACHED THE HEMODYNAMIC THERAPEUTIC PLASMA THRESHOLD FASTER THAN EPIPEN PK Parameters EpiPen NS002 4mg Cmax (Mean) (pg/ml) 360 477 Tmax (Median) (Minutes) 15 10 NASAX® POWDER WAS WELL TOLERATED
Slide 23: The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine
The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine PK Parameters ARS Pharma1 Bryn Pharma2 Orexo3 Aquestive4 Cmax (Mean) 341 429 377 497 (pg/ml) Tmax (Median) 30 20 25 15 (Minutes) AUC 0-10 min 712 1,130 912 1,074 (h/pg/ml) AUC 0-30 min 4,901 6,789 5,796
Slide 24: NS002: Milestones and Pathway Forward
NS002: Milestones and Pathway Forward Completed NS002 Complete Nasax® tech Submit Initiate NS002 pilot study transfer and scaled NS002 IND pediatric study Q3 2021 commercial production Q3 2026 Q4 2026 Q3 2025 Completed NS002/EpiPen Submit NS002 Initiate additional Initiate NS002 pivotal Comparative
Slide 25: Nasus is Uniquely Positioned to Address Medical Emergencies
Nasus is Uniquely Positioned to Address Medical Emergencies Proprietary Nasax® technology aims to enhance intranasal drug absorption Lead asset NS002 designed as a needle-free, convenient, easily administered alternative to Epinephrine autoinjector, directly addressing the current unmet need Positiv
Slide 26: Pre-Offering Capitalization Table
Pre-Offering Capitalization Table Shares Outstanding* 7,759,999 Employee Options (WAEP: $4.88) 538,237 Warrants 0 Fully Diluted Shares Outstanding 8,298,236 * Gives effect to 397,093 Ordinary Shares issuable upon the conversion of SAFEs entered into between March 2024 and March 2025, which will auto
Slide 27: Robust Patent Portfolio
Robust Patent Portfolio Country Filed Patent No./ Publication No. Grant Date/ Pub. Date Status Expiration Date(2) USA 8/20/2017 Term Ended PCT(1) 8/19/2018 WO 2019/038756 A1 National Phase entered 8/19/2038 Australia 8/19/2018 Grant Fee Paid 8/19/2038 Canada 8/19/2018 Office Action due: 10/22/2024 8
Slide 28: Leadership Team
Leadership Team Udi Gilboa Dan Teleman Dalia Megiddo, MD Oren Elmaliach, CPA Tair Lapidot, PhD Co-Founder & Executive Chairman Chief Executive Officer Co-Founder & Chief Development Officer Director of Finance VP of Pre-Clinical & Clinical Development Mr. Gilboa is a prominent serial life Mr. Dan Te
Slide 29: Thank You
THANK YOU A NEW FRONTIER IN INTRANASAL DRUG DELIVERY 29